Pancreas targeting
Carrier and targeting approaches designed to increase drug exposure or selectivity in pancreatic tissue.
SMDC
Small Molecule Drug Conjugates
Small-molecule conjugates, engineered for tissue selectivity.
The opportunity
The value of a drug depends on where it acts
A pharmacologically active molecule may still be limited by systemic exposure, off-target effects or insufficient concentration in the target tissue.
Controlling its distribution creates a better relationship between efficacy and tolerability.
The platform
Restricting drug action to the relevant tissue
SMDC combines active molecules with carriers or targeting ligands designed to influence where a drug is absorbed, distributed or activated.
Selective distribution
A broader design framework for evaluating how molecular conjugation may improve the distribution of a therapeutic candidate.
Potential applications
Creating value through controlled exposure
A programme may begin with a 4Ammonium conjugate or with an active molecule supplied by a partner.
Restrict
Reduce unwanted exposure beyond the intended site of action.
Direct
Explore greater exposure or selectivity in a relevant tissue.
Differentiate
Create a new development opportunity for an active small molecule.
Partnering
Apply SMDC to a molecule or programme
Contact us to explore whether a tissue-targeting strategy could create a differentiated opportunity.
Discuss an SMDC application